Latest Regulatory News

Yowie Group has appointed Jesse Hamilton as its new Company Secretary, following the resignation of John Patton. The company also confirmed the automatic termination of executive roles held by former directors Nicholas Bolton and John Patton.

Peninsula Energy has locked in a $15 million debt facility from Davidson Kempner to advance commissioning at its Lance uranium project and support an upcoming equity raise. The funding aims to sustain momentum towards production resumption and ASX relisting.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.

Ausgold Limited has raised A$35 million through a well-supported placement to accelerate its Katanning Gold Project in Western Australia towards a final investment decision.

Chariot Corporation Ltd is set to acquire a 66.7% interest in a substantial Nigerian lithium portfolio, marking a strategic entry into Africa’s burgeoning lithium sector with a US$10 million funding commitment.

Aguia Resources has locked in $2.687 million in loan commitments, including a $500,000 stake from its Executive Chairman, to fund ongoing mine development and exploration in Colombia. The loans feature convertible terms and options issuance, pending shareholder and ASX approvals.

Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

Australian Rare Earths Limited (ASX, AR3) has acquired exploration license EL6895, adding 972 km² to its Overland Uranium Project and uncovering significant near-surface uranium potential from historic data. Drilling is set to resume in July 2025 to test this promising new target alongside existing deeper uranium prospects.

Osmond Resources has significantly expanded its Orion EU Critical Minerals Project by 160%, with promising assay results and a planned drilling program to confirm mineral continuity. The company is positioning itself to benefit from strong EU demand for rare earths, titanium, and silicon metals.

Race Oncology has secured key ethics approvals to launch its Phase 1 RC220 trial at two major Hong Kong hospitals, marking a strategic expansion beyond Australia to accelerate patient recruitment and explore cardioprotective benefits.

Orthocell has achieved a significant milestone by recording its first US sales revenue for Remplir™, its flagship nerve repair product, shortly after FDA clearance and initial surgical use.